<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Eur J Nucl Med Mol Imaging</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>European journal of nuclear medicine and molecular imaging</journal-title></journal-title-group><issn pub-type="ppub">1619-7070</issn><issn pub-type="epub">1619-7089</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8279045</article-id><article-id pub-id-type="pmcid-ver">PMC8279045.1</article-id><article-id pub-id-type="pmcaid">8279045</article-id><article-id pub-id-type="pmcaiid">8279045</article-id><article-id pub-id-type="manuscript-id">NIHMS1720534</article-id><article-id pub-id-type="pmid">33047248</article-id><article-id pub-id-type="doi">10.1007/s00259-020-05050-z</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1720534</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1720534</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Intra-Ommaya Compartmental Radioimmunotherapy using <sup>131</sup>I-Omburtamab&#8212; Pharmacokinetic Modeling to Optimize Therapeutic Index</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Yerrabelli</surname><given-names initials="RS">Rahul S.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7670-9601</contrib-id><xref ref-type="aff" rid="A1">[1]</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="P">Ping</given-names></name><xref ref-type="aff" rid="A2">[2]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fung</surname><given-names initials="EK">Edward K.</given-names></name><xref ref-type="aff" rid="A3">[3]</xref><xref ref-type="aff" rid="A4">[4]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kramer</surname><given-names initials="K">Kim</given-names></name><xref ref-type="aff" rid="A1">[1]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zanzonico</surname><given-names initials="PB">Pat B.</given-names></name><xref ref-type="aff" rid="A3">[3]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Humm</surname><given-names initials="JL">John L.</given-names></name><xref ref-type="aff" rid="A3">[3]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guo</surname><given-names initials="H">Hongfen</given-names></name><xref ref-type="aff" rid="A1">[1]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pandit-Taskar</surname><given-names initials="N">Neeta</given-names></name><xref ref-type="aff" rid="A5">[5]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Larson</surname><given-names initials="SM">Steven M.</given-names></name><xref ref-type="aff" rid="A5">[5]</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cheung</surname><given-names initials="NKV">Nai-Kong V.</given-names></name><xref ref-type="aff" rid="A1">[1]</xref></contrib></contrib-group><aff id="A1"><label>1.</label>Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA</aff><aff id="A2"><label>2.</label>Renaissance School of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY 11794, USA</aff><aff id="A3"><label>3.</label>Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA</aff><aff id="A4"><label>4.</label>Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065</aff><aff id="A5"><label>5.</label>Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA</aff><author-notes><fn fn-type="present-address" id="FN1"><label>*</label><p id="P1">Current Address: Rahul S. Yerrabelli, B.S. (Medical Student), Carle Illinois College of Medicine, University of Illinois at Urbana-Champaign, 807 South Wright Street, Champaign, Illinois 61820</p></fn><corresp id="CR1"><bold>Corresponding Author:</bold> Nai-Kong V. Cheung, MD PhD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, (Office) 646-888-2313, (Fax) 646-422-0452, <email>cheungn@mskcc.org</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2021</year></pub-date><volume>48</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">385656</issue-id><fpage>1166</fpage><lpage>1177</lpage><pub-history><event event-type="nihms-submitted"><date><day>04</day><month>07</month><year>2021</year></date></event><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-11 11:25:15.547"><day>11</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><ali:license_ref>http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1</ali:license_ref><license-p>Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1">http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1720534.pdf"/><abstract id="ABS1"><sec id="S1"><title>Purpose:</title><p id="P2">Radioimmunotherapy (RIT) delivered through the cerebrospinal fluid (CSF) has been shown to be a safe and promising treatment for leptomeningeal metastases. Pharmacokinetic models for intra-Ommaya anti-GD2 monoclonal antibody <sup>131</sup>I-3F8 have been proposed to improve therapeutic effect while minimizing radiation toxicity. In this study, we now apply pharmacokinetic modeling to intra-Ommaya <sup>131</sup>I-omburtamab (8H9), an anti-B7-H3 antibody which has shown promise in RIT of leptomeningeal metastases.</p></sec><sec id="S2"><title>Methods:</title><p id="P3">Serial CSF samples were collected and radioassayed from 61 patients undergoing a total of 177 intra-Ommaya administrations of <sup>131</sup>I-omburtamab for leptomeningeal malignancy. A two-compartment pharmacokinetic model with 12 differential equations was constructed and fitted to the radioactivity measurements of CSF samples collected from patients. The model was used to improve anti-tumor dose while reducing off-target toxicity. Mathematical endpoints were (a) the area under the concentration curve (AUC) of the tumor-bound antibody, AUC[C<sub>IAR</sub>(t)], (b) the AUC of the unbound &#8220;harmful&#8221; antibody, AUC[C<sub>IA</sub>(t)], and (c) the therapeutic index, AUC[C<sub>IAR</sub>(t)]&#247;AUC[C<sub>IA</sub>(t)].</p></sec><sec id="S3"><title>Results:</title><p id="P4">The model fit CSF radioactivity data well (mean R=96.4%). The median immunoreactivity of <sup>131</sup>I-omburtamab matched literature values at 69.1%. Off-target toxicity (AUC[C<sub>IA</sub>(t)]) was predicted to increase more quickly than AUC[C<sub>IAR</sub>(t)] as a function of <sup>131</sup>I-omburtamab dose, but the balance of therapeutic index and AUC[C<sub>IAR</sub>(t)] remained favorable over a broad range of administered doses (0.48&#8211;1.40mg or 881&#8211;2592MBq). While anti-tumor dose and therapeutic index increased with antigen density, the optimal administered dose did not. Dose fractionization into two separate injections increased therapeutic index by 38%, and splitting into 5 injections by 82%. Increasing antibody immunoreactivity to 100% only increased therapeutic index by 17.5%.</p></sec><sec id="S4"><title>Conclusion:</title><p id="P5">The 2-compartmental pharmacokinetic model when applied to intra-Ommaya <sup>131</sup>I-omburtamab yielded both intuitive and non-intuitive therapeutic predictions. The potential advantage of further dose fractionization warrants clinical validation.</p></sec><sec id="S5"><title>Clinical Trial Registration:</title><p id="P6"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00089245">NCT00089245</ext-link></p></sec></abstract><kwd-group><kwd>Radioimmunotherapy</kwd><kwd>Cerebrospinal fluid</kwd><kwd>Pharmacokinetics</kwd><kwd>Neuroblastoma</kwd><kwd><sup>131</sup>I-omburtamab</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>